Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3355072 | Immunology and Allergy Clinics of North America | 2007 | 12 Pages |
Abstract
Among patients with hypereosinophilia, a myeloproliferative variant is recognized. In many of these patients a diagnosis of eosinophilic leukemia can be made. The molecular mechanism is often a fusion gene, incorporating part of PDGFRA or PDGFRB, encoding anaberrant tyrosine kinase. Prompt diagnosis of such cases is important since specific tyrosine kinase inhibitor therapy is indicated.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Barbara J. MBBS, FRACP, FRCPath, Sarah H. MBBChir, MRCP,